|
ACE2 and Covid
|
8
|
Resverlogix Corp.
|
Sep 25, 2020 11:05AM
|
|
apabetalone and colorectal cancer
|
7
|
Resverlogix Corp.
|
Nov 12, 2018 11:12PM
|
|
balancing success and failure
|
12
|
Resverlogix Corp.
|
Nov 19, 2019 06:52PM
|
|
BRD2 involvement in Covid19
|
14
|
Resverlogix Corp.
|
Mar 18, 2020 12:03PM
|
|
Congestive heart failure
|
8
|
Resverlogix Corp.
|
Nov 25, 2019 02:14PM
|
|
Multiple endpoints
|
4
|
Resverlogix Corp.
|
Oct 31, 2019 01:47PM
|
|
orphan diseases
|
4
|
Resverlogix Corp.
|
Jun 30, 2018 10:57PM
|
|
Presentation available
|
2
|
Resverlogix Corp.
|
Jun 10, 2020 10:47AM
|
|
Re: A few thoughts
|
5
|
Resverlogix Corp.
|
Nov 16, 2019 06:40PM
|
|
Re: A hunch about the below median LDL-C observation
|
3
|
Resverlogix Corp.
|
Nov 20, 2019 03:31PM
|
|
Re: A hunch about the below median LDL-C observation
|
3
|
Resverlogix Corp.
|
Nov 20, 2019 03:44PM
|
|
Re: A New Frontier in CV Risk Reduction for Patients With Type 2 Diabetes
|
7
|
Resverlogix Corp.
|
Dec 17, 2018 11:48AM
|
|
Re: AAC Poster Question on MoCA
|
8
|
Resverlogix Corp.
|
Mar 21, 2019 07:43PM
|
|
Re: ACC 2019 Abstracts
|
4
|
Resverlogix Corp.
|
Mar 19, 2019 02:36PM
|
|
Re: ACC 2019 Abstracts
|
4
|
Resverlogix Corp.
|
Mar 19, 2019 03:24PM
|
|
Re: ACC 2019 Abstracts
|
4
|
Resverlogix Corp.
|
Mar 19, 2019 07:31PM
|
|
Re: ACC 2019 Abstracts
|
3
|
Resverlogix Corp.
|
Mar 04, 2019 03:40PM
|
|
Re: ACC 2019 Abstracts
|
3
|
Resverlogix Corp.
|
Mar 04, 2019 11:04PM
|
|
Re: ACE2 and Covid
|
2
|
Resverlogix Corp.
|
Sep 25, 2020 06:29PM
|
|
Re: ACE2 and Covid....Link to the Lancet article:
|
3
|
Resverlogix Corp.
|
Sep 25, 2020 12:29PM
|
